Salvage cryotherapy for recurrent prostate cancer after radiation failure: Current status and future perspectives

Therapy

Volumn 5, Issue 1, 2008, Pages 37-45

  Ismail, Mohamed ^a   Hardev, Pandha ^a   Davies, John ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cryoimmunotherapy; Cryotherapy; Focal cryotherapy; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; FLUOROURACIL; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRYOABLATION; CRYOTHERAPY; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEALTH CARE COST; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMPOTENCE; LOW LEVEL LASER THERAPY; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE SURGERY; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PROCESS OPTIMIZATION; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECTUM FISTULA; RECTUM INJURY; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR IMMUNITY; URINARY CATHETER; URINE INCONTINENCE; WARMING;

EID: 38349136454     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.1.37     Document Type: Review

References (81)

1. Arai Y, Kanamaru H, Morol S. Ishitoya S, Okubo K, Suzuki Y, Yoshida O: Radical prostatectomy for clinically localized prostate cancer: local tumor extension and prognosis. Int. J Urol. 3(5), 373-378 (1996).
2. Kupelian P, Katcher J, Levin H, Zippe C, Sub J, Macklis R, Klein E: External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J. Sci. Am. 3(2), 78-87 (1997).
3. Lim AJ, Brandon AH, Fiedler J et al.: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J. Urol. 154(4), 1420-1425 (1995).
4. Aus G, Abbou CC. Bolla M et al.: EAU guidelines on prostate cancer. Eur. Urol. 48(4), 546-551 (2005).
5. D'Amico AV, Whittington R, Malkowicz SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969-974 (1998).
6. Kavadi VS. Zagars GK, Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J Radiat. Oncol. Biol. Phys. 30(2), 279-287 (1994).
7. Hancock SL, Cox RS, Bagshaw MA: Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J. Urol. 154(4). 1412-1417 (1995).
8. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM: Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15), 1395-1400 (1999).
9. Denis L, Murphy GP: Overview of Phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72(Suppl. 12), 3888-3895 (1993).
10. Comes DM, Goffinet DR, Martinez A, Stamey TA: Complication of 125 Iodine implantation and pelvic lymphadenectomy for prostatic cancer with special reference to patients who had failed external beam therapy as their Initial mode of therapy. J. Urol. 126(5), 620-622 (1981).
11. Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol. 173(2), 373-379 (2005).
12. Flocks RH, Nelson CM, Boatman DL: Perineal cryosurgery for prostatic carcinoma. J. Urol. 108(6). 933-935 (1972).
13. Onik GM, Cohen JK. Reyes GD, Rubinsky B, Chang Z, Baust J: Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72(41), 1291-1299 (1993).
14. Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL, Tom WL: Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer 79(5), 963-974 (1997).
15. de la Taille A, Hayek O, Benson MC et al.: Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 55(1), 79-84 (2000).
16. Ghafar MA, Johnson CW, de la Taille A et al.: Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J. Urol. 166(4), 1333-1337 (2001).
17. Mobley WC, Loening SA, Narayana AS: Combination perineal cryosurgery and external radiation therapy for adenocarcinoma of prostate. Urology 24(1), 11-14 (1984).
18. Chin JL, Pautler SE, Mouraviev V, Tourna N, Moore K, Downey DB: Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J. Urol. 165(6 Pt 1), 1937-1941 (2001).
19. Han KR, Cohen JK, Miller RJ et al.: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 170(4 Pt 1). 1126-1130 (2003).
20. Bahn DK, Lee F, Silverman P et al.: Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin. Prostate Cancer 2(2), 111-114 (2003).
21. Katz AE. Ghafar MA: Selection of salvage cryotherapy patients. Rev. Urol. 4(Suppl. 2) S18-S23 (2002).
22. Chan TY, Chan DY. Stutzman KL, Epstein, JI: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J. Urol. 166(6), 2181-2184 (2001).
23. Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother. Oncol. 57(3), 273-278 (2000).
24. Katz AE, Ghafar MA: Selection of salvage cryotherapy patients. Rev. Urol. 4(Suppl 2) S18-S23 (2002).
25. Gillett MD, Gettman MT, Zincke HT, Blute ML: Tissue ablation technologies for localized prostate cancer. Mayo Clin. Proc. 79(12), 1547-1555 (2004).
26. Ismail M, Ahmed S, Kastner C, Davies J: Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU. Int. 100(4), 760-764 (2007).
27. Robinson JW, Donnelly BJ, Coupland K et al.: Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol. Oncol. 24(6), 472-486 (2006)
28. Cohen JK: Cryosurgical ablation of the prostate: pro. Urology 48(2), 178-180 (1996).
29. Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL: Qulity of life after salvage cryotherapy: the impact of treatment parameters. J. Urol. 162(2), 398-402 (1999).
30. Link P, Freiha FS: Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 37(3), 189-192 (1991).
31. Bales GT, Williams MJ, Sinner M, Thisted RA, Chodak GW: Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 46(5), 676-680 (1995).
32. Pisters LL. von Eschenbach AC, Scott SM et al.: The efficacy and complicitions of salvage cryotherapy of the prostate. J. Urol. 157(3), 921-925 (1997).
33. Ward JF, Sebo TJ, Blute ML, Zincke H: Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J. Urol. 173(4), 1156-1160 (2005).
34. Rogers E, Ohori M, Kassabian VS, Wheeler M, Scardino PT: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J. Urol. 153(1), 104-110 (1995).
35. Chin JL, Touma N, Pautler SE et al.: Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure. J. Urol. 170(4 Pt 1), 1199-1202 (2003).
36. Gould RS: Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. J. Urol. 162(5), 1653-1657 (1999).
37. Benoit RM, Cohen JK, Miller RJ Jr.: Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology 52(5), 820-824 (1998).
38. Gelet A, Chapelon JY, Poissonnier L et al.: Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63(4), 625-629 (2004).
39. Connolly JA, Shinohara K, Carroll PR: Cryosurgery for locally advanced (T3) prostate cancer. Semin. Urol. Oncol. 15(4), 244-249(1997).
40. Onik G: Rationale for a "male lumpectomy" a prostate cancer targeted approach using cryoablation: Results in 21 patients with at least 2 years of follow-up. Cardiovasc. Intervent. Radiol. (2007) (In press).
41. Janzen NK, Han KR, Perry KT, Said JW, Schulam PG, Belldegrun AS: Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J. Endourol. 19(4), 520-525 (2005).
42. Lambert EH, Bolte K, Masson P, Katz AE: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69(6), 1117-1120 (2007).
43. Romero-Méndez R, Franco W, Aguilar G: Laser-assisted cryosurgery of prostate: numerical study. Phys. Med. Biol. 52(2), 463-478 (2007).
44. Cytron S, Paz A, Kravchick S, Shumalinski D, Moore J: Active rectal wall protection using direct transperineal cryoneedles for histologically proven prostate adenocarcinomas. Eur. Urol. 44(3), 315-320 (2003).
45. Jones JS: Ultrasound probe positioning to minimize the risk of recto urethral fistula during cfyosurgical ablation of prostate cancer. BJU. Int. 100(1), 58-62 (2007).
46. Dow JA, Waterhouse K: An experimental study in lethal freezing temperatures of the prostate gland. J. Urol. 103(4), 454-457 (1970).
47. Cooper IS: Cryobiology as viewed by the surgeon. Cryobiology 51, 44-51 (1964).
48. Tatsutani K, Rubinsky B, Onik G, Dahiya R: Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology 48(3), 441-447 (1996).
49. Gage AA, Guest K, Montes M, Caruana JA, Whalen DA Jr: Effect of varying freezing and thawing rates in experimental cryosurgery. Cryobiology 22(2), 175-182 (1985).
50. Gage AA: What temperature is lethal for cells? J. Dermatol. Surg. Oncol. 5(6), 459-464 (1979).
51. Bischof JC, Smith D, Pazhayannur PV, Manivel C, Hulbert J, Roberts KP: Cryosurgery of dunning AT-1 rat prostate tumor: thermal, biophysical and viability response at the cellular and tissue level. Cryobiology 34(1), 42-69 (1997).
52. Gage AA, Baust J: Mechanisms of tissue injury in cryosurgery. Cryobiology 37(3), 171-186 (1998).
53. Larson TR, Rrobertson DW, Corica A, Bostwick DG: In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology 55(4), 547-552 (2000).
54. Baust JG, Gage AA: The molecular basis of cryosurgery. BJU Int. 95(9), 1187-1191 (2005).
55. Hollister W, Mathew A, Baust J, Van Buskirk R: Effect of freezing on cell viability and mechanisms of cell death in human prostate cancer cell lines. Mol. Urol. 2(1), 13-18 (1998).
56. Baust JG, Gage AA, Clarke D, Baust JM, Van Buskirk R: Cryosurgery - a putative approach to molecular-based optimization. Cryobiology 48(2), 190-204 (2004).
57. Clarke DM, Robilotto AT, VanBuskirk RG, Baust JG, Gage AA, Baust JM: Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic. Dis. 10(2), 175-184 (2007)
58. Clarke DM, Baust JM, Van Buskirk RG, Baust JG: Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology 49(1), 45-61 (2004).
59. Goel R, Swanlund D, Coad J. Paciotti GF, Bischof JC: TNF-α-based accentuation in cryoinjury-dose, delivery, and response. Mol. Cancer Ther. 6(7), 2039-2047 (2007)
60. Soanes WA, Gonder MJ, Ablin RJ: A possible immuno-cryothermic response in prostatic cancer. Clin. Radiol. 21(3), 253-255 (1970).
61. Soanes WA, Ablin RJ, Gonder MJ: Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J. Urol. 104(1), 154-159 (1970).
62. Gursel E, Roberts M, Veenema RJ: Regression of prostatic cancer following sequential cryotherapy to the prostate. J. Urol. 108(6), 928-932 (1972).
63. den Brok MH, Sutmuller RP, van der Vort R et al.: In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64(11), 4024-4029 (2004).
64. Joosten JJ, Muijen GN, Wobbes T, Ruers TJ: In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology 42(1), 49-58 (2001).
65. Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE: Immunologic response to cryoablation of breast cancer. Breast Concer Res. Treat. 90(1), 97-104 (2005).
66. Grana L, Ablin RJ, Goldman S, Milhouse E Jr: Freezing of the esophagus: histological changes and immunological response. Int. Surg. 66(4), 295-301 (1981).
67. Bonney WW, Henstorf JE, Emaus SP, Lubaroff DM, Feldbush TL: Immunostimulation by cryosurgery: an orthotopic model of prostate and bladder cancer in the rat. Natl. Cancer Inst. Monogr. (49), 375-381 (1978).
68. Fazio M, Airoldi M, Mastromatteo V, Negri L, Gandolfo S, Furlani D: Cryosurgery as a stimulator of the host's immune defences in benign and malignant oral cavity tumours. Panminerva Med. 24(3), 195-201 (1982).
69. Fukagai T, Tazawa K. Higaki Y, Imamura K: Changes in immunoparameters following cryosurgery in prostate cancer. Hinyokika Kiyo. 36(3), 307-317 (1990).
70. Javadpour N, Bagley DH, Zbar B: Failure of cryosurgical treatment of experimental Intradermal tumor's to eradicate microscopic lymph node metastases in guinea pigs. J. Natl. Cancer Inst. 62(6), 1479-1481 (1979).
71. Muller LC, Micksche M, Yamagata S, Kerschbaumer F: Therapeutic effect of cryosurgery of murine osteosarcoma - influence on disease outcome and immune function. Cryobiology 22(1), 77-85 (1985).
72. Hoffmann NE, Coad JE, Huot CS, Swanlund DJ, Bischof JC: Investigation of the mechanism and the effect of cryoimmunology in the Copenhagen rat. Criobiology 42(1), 59-68 (2001).
73. Friedman EJ, Orth CR, Brewton KA, Ponniah S, Alexander RB: Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge. J. Urol. 158(4), 1585-1588 (1997).
74. Yantorno C, Soanes WA, Gonder MJ, Shulman S: Studies in cryo-immunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology 12(4), 395-410 (1967).
75. Moore FT, Blackwood J, Sanzenbacher L, Pace WG: Cryotherapy for malignant tumors. Immunologic response. Arch. Surg. 96(4), 527-529 (1968).
76. Hayakawa K, Yamashita T, Suzuki K et al.: Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholanthrene-induced primary autochthonous tumors. Genn. 73(3), 462-469 (1982).
77. Udagawa M, Kudo-Saito C, Hasegawa G et al.: Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin. Cancer Res. 12(24), 7465-7475 (2006).
78. Machlenkin A, Goldberger O, Tirosh B et al.: Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin. Cancer Res. 11(13), 4955-4961 (2005).
79. Collins SM, Kozakowski K, Katz A: In: Handbook of urologic cryoablation. (Ed), Rukstalis DB and Katz A, Informa Healthcare, 47-57 (2007).
80. Lam JSLJ, Leppert JT, Koski ME, Vemulapalli SN, Belldegrun AS: Salvage cryosurgical ablation for radiorecurrent prostate cancer using third generation cryoneedles: The University of California-Los Angeles experience. J. Urol. 173, 181 (AUA Annual Meeting Program (2005) (Abstracts 665).
81. Bayjoo P, Rees RC, Goepel JR, Jacob G: Natural killer cell activity following cryosurgery of normal and tumour bearing liver in an animal model. J Clin. Lab. Immunol. 35(3), 129-132 (1991).